Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

169
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
169
Drug Classes and Categories01:25

Drug Classes and Categories

2.7K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
2.7K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

97
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
97
Drug Nomenclature01:17

Drug Nomenclature

2.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.8K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

138
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of software vs. cognitive-based fusion-targeted biopsies for prostate cancer diagnosis.

BJUI compass·2026
Same authorSame journal

[Access to health data for research].

Lakartidningen·2026
Same author

Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study.

European urology open science·2026
Same author

Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical Prostatectomy.

European urology open science·2026
Same author

Extent of prostate cancer cases not registered in The National Cancer Register of Sweden and consequences for estimates of prostate cancer incidence and mortality.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden.

Acta oncologica (Stockholm, Sweden)·2026

Related Experiment Video

Updated: Dec 21, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K

[Medicinal products in unauthorised indications].

Veronica Arthurson1, Karl-Mikael Kälkner2, Rolf Gedeborg3

  • 1docent, gruppchef, Läkemedelsverket, Uppsala.

Lakartidningen
|May 21, 2020
PubMed
Summary

The Medical Products Agency found no new safety concerns regarding off-label rituximab use in multiple sclerosis (MS) patients. However, confirmed efficacy data is lacking, leaving the benefit-risk balance undetermined for this MS treatment.

More Related Videos

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.4K
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

11.2K

Related Experiment Videos

Last Updated: Dec 21, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.4K
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

11.2K

Area of Science:

  • Pharmacology and Therapeutics
  • Neurology
  • Regulatory Science

Background:

  • Rituximab is used off-label for active multiple sclerosis (MS).
  • Regulatory assessments are crucial for evaluating unapproved indications of medications.
  • The Medical Products Agency (MPA) evaluated rituximab's use in MS.

Purpose of the Study:

  • To assess the safety and efficacy of off-label rituximab use in patients with active MS.
  • To determine the benefit-risk balance of rituximab for MS from a regulatory standpoint.

Main Methods:

  • Review of pharmacodynamic data.
  • Analysis of early-phase clinical trial data.
  • Evaluation of non-interventional study data on effectiveness.

Main Results:

  • No new safety concerns were identified for off-label rituximab in active MS.
  • Plausible data supports rituximab's biological effects in MS.
  • Reliable confirmation of efficacy magnitude in a defined population and dosage is lacking.

Conclusions:

  • The benefit-risk balance for rituximab in MS patients is currently undetermined from a regulatory perspective.
  • No regulatory action is needed based on current safety data.
  • MPA recommends against a standardized procedure for evaluating benefit-risk in unauthorized indications.